RYSE Asset Management: Novartis Pharmaceuticals UK launches world-first health-tech investor partnership to reimagine cardiovascular care
Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.
The ambitious initiative has a bold aim – to identify and implement solutions that empower patients to improve their heart health, and to help prevent future heart attacks or strokes through home-based digital solutions. The focus is on the major risk factors, non-invasive ways of lipid testing and blood pressure management using software as a medical device (SaMD).
Applications are open to health-tech start-up founders, researchers, and technologists working on innovative solutions to enable system-wide change in cardiovascular disease (CVD) patient care pathways.
The Novartis Biome UK is leading this first of its kind investor partnership, combining its patient pathway knowledge with Medtronic’s experience as the global leader in healthcare technology. RYSE Asset Management, the specialist healthcare investor, will provide up to £3 million in investment and the CW Innovation programme – a collaboration between Chelsea and Westminster Hospital NHS Foundation Trust and CW+ – will work to establish a real-world clinical evaluation for selected solutions.
Marie-Andrée Gamache, Country President, Novartis Innovative Medicines UK and Ireland, comments: “I am confident that this bold partnership can deliver significant progress within the UK health system, as well as real change for the seven million people in the UK who are living with CVD1. Through leveraging digital solutions, new models of care, and leading on cross- industry and investor collaboration, Novartis Pharmaceuticals UK is accelerating sustainable action on health inequalities at pace and scale.”
The Novartis Biome Heart Health Catalyst 2022 aims to spark a revolution in CVD care by identifying and scaling innovations in the at-home blood pressure management and non- invasive lipid testing space. Successful applicants will receive:
- Unrivalled support and knowledge from industry-leading and investor partners
- Investment of up to £3 million and access to a global network of established distribution partners from RYSE Asset Management
- Access to the Novartis Biome UK system
- Immediate NHS pilot and validation opportunities.
Bhavesh Barot, Medtronic UK & Ireland Regional Vice President, comments: “As the global leader in healthcare technology, we are pleased to be a partner in the Novartis Biome UK Heart Health Catalyst. This programme aligns with our commitment for innovation – taking an idea, nurturing it, and turning it into real-world, ground-breaking reality. We are excited about the opportunity this programme presents to propel new solutions and the benefits that will bring to healthcare providers and patients living with CVD.”
Vivien de Tusch-Lec, General Partner at RYSE Asset Management, said: “Partnering with healthcare innovators to scale and deliver transformation is in our DNA at RYSE. Such collaborations enable us to better understand the challenges faced by public and private healthcare providers, corporates and consumers and identify technology gaps to promote truly disruptive businesses. The Novartis Biome UK Heart Health Catalyst 2022 presents a natural collaboration opportunity which we see delivering for the UK health system and patients.”
Chris Chaney, Chief Executive Officer at CW+ and co-lead of CW Innovation, said: “The Covid- 19 pandemic has demanded the radical acceleration of our digital health programmes and this, coupled with a surge in new thinking and innovation across our organisation, makes the launch of the Novartis Biome UK Heart Health Catalyst 2022 both timely and relevant.
“We are therefore delighted to collaborate on this new initiative, working with partners, and providing the winner with the opportunity to test and scale their innovation at Chelsea and Westminster Hospital NHS Foundation Trust as part of our flagship CW Innovation programme.
“In this period of significant change and challenge, our absolute focus is on providing the best possible care for our patients, and we look forward to working with the winners of the Catalyst to help improve and enhance the care and experience of CVD patients.”
Applications for the Novartis Biome UK Heart Health Catalyst 2022 open today and close on the 31 August 2022. Shortlisted organisations and individuals will be invited to a Pitchfest in front of an expert audience from across the healthcare system at the Healthcare Excellence Through Technology (HETT) conference on 27/28 September 2022, where the winners will subsequently be announced.
Are you a health-tech start-up founder, innovator, researcher, or technologist?
Find out more about the Novartis Biome UK Heart Health Catalyst 2022 and apply here: https://biome.novartis.com/innovation-hubs/novartis-biome-uk/uk-health-catalyst-2022- application-form
– ENDS –
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we strive to use innovative science and digital technologies to create treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials, in the UK.
For more information, please visit www.novartis.co.uk.
About Novartis Biome
Founded in 2018, the Novartis Biome is a catalyst for impactful collaboration. The Biome brings together Novartis’ deep scientific experience with the expertise of the tech ecosystem to develop and scale digital solutions that improve and extend people’s lives. The Biome allows internal and external teams to co-develop digital solutions alongside specific therapeutic offerings, research activities, and business processes within Novartis. Launched in 2020 striving to test and learn fast, the Novartis Biome UK is located in the heart of London, focusing on scaling innovative solutions for chronic and long-term disease management. To date, the Biome UK has successfully scouted, tested and scaled a digital patient management solution to help tackle the patient backlog called Penguin and successfully launched its first ever Evidence Lab test in a real clinical environment.
For more information, please visit https://www.biome.novartis.com/
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
For more information on Medtronic (NYSE:MDT), please visit http://www.medtronic.com/
About RYSE Asset Management
RYSE Asset Management (RYSE) is a specialist healthcare investor with a focus on impact. Since 2015, RYSE has been supporting technology companies to achieve accelerated global growth and scale by connecting high-potential healthcare founders with established distribution partners. In 2018/20, RYSE DigitalHealth.London investment programmes translated great ideas into real-world solutions. RYSE partners with founders with clinical experience who know how to serve patients best and with investors that share RYSE’s ambition to transform the future of healthcare, improving quality and access.
For more information, please visit https://www.ryseam.com/en/ and follow us on LinkedIn https://www.linkedin.com/company/ryse-asset-management-llp/.
About Chelsea and Westminster Hospital NHS Foundation Trust
Chelsea and Westminster Hospital NHS Foundation Trust is one of the top ranked and top performing hospital trusts in the UK. We employ more than 6,000 staff over our two main hospital sites, Chelsea and Westminster Hospital and West Middlesex University Hospital, and across 12 community-based clinics within North West London. We were rated Outstanding for Well-Led and Use of Resources by the Care Quality Commission.
Both hospitals have major A&E and urgent care departments, treating over 500,000 patients in a typical year. The Trust is one of the largest maternity services in England, delivering over 10,000 babies last year. Our specialist care includes the world-renowned burns service, which
is the leading centre in London and the South East; we run Chelsea Children’s Hospital with paediatric inpatient and outpatient services; and our specialist HIV and award-winning sexual health care services.
In partnership with CW+ our hospital charity we build and enhance clinical facilities to create an outstanding care environment for our patients and for our staff.
We are an emerging leader for innovation within the NHS. Our CW Innovation programme is led jointly by the Trust and CW+ and has led to a number of successful projects adopted elsewhere in the NHS.
RYSE Asset Management
1 NHS. Cardiovascular disease (CVD). https://www.england.nhs.uk/ourwork/clinical-policy/cvd/ [Last accessed: June 2022]